Strides Group News Today

Thanks, arthur. Lets bring you up to speed on crisis in iraq. Bullet points for today. Isis has taken out are ttilleryd trucks. The president authorizing the air strikes and emergency food drops to help religious minorities surrounded by the militants unable to get away. The bombing was done by two u. S. F18s dropping laser guided bombs on isis which in the last week took over six towns in Northern Iraq and the mosul dam which controls electricity to much of the country. Doug is live for us at t...

COVID-19 clinical trial pipeline constitutes 420+ key companies continuously working towards developing 520+ COVID-19 vaccines and drugs, analyzes DelveInsight LAS VEGAS, Nov. 8, 2022 /PRNewswire/

The multicenter trial will complete the enrollment of 1,500 healthy volunteers, age 18 and older, who will receive two 90 µg doses 28 days apart, the company stated.

BEVERLY, Mass. & BANGALORE, India--(BUSINESS WIRE)--Apr 7, 2022--

Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster - read this article along with other careers information, tips and advice on BioSpace

Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries - read this article along with other careers information, tips and advice on BioSpace

Biolexis will launch AKS-452 as “AmbiVax-CTM” for global markets where the cold chain elimination would contribute to improving immunization coverage and reducing vaccine wastage

Massachusetts-based Akston Biosciences Corporation and Biolexis announced today that they have entered into a licensing, manufacturing, and commercialization agreement for Akston's AKS-452, a protein subunit COVID-19 vaccine. Under the agreement, Biolexis gains the right to manufacture and commercialize AKS-452 (branded as AmbiVax-CTM) in India and over 130 countries in Asia, Latin America, and Africa.

Procaps Group, a leading integrated international healthcare and pharmaceutical company, today announced the closing of an asset purchase agreement to acquire an 86,000ft² pharmaceutical production facility located in

A new drug application of Amphotericin B Liposome injection 50 mg filed by Nasdaq-listed Taiwanese clinical-stage specialty pharmaceutical firm TLC has been approved by the Central Drugs Standard Cont